Skip to content

Validation of a Capillary Leak Index During Septic Shock, Based on Haemoglobin Level Variations Induced by Fluid Resuscitation. A Pilot Study.

Validation of a Capillary Leak Index During Septic Shock, Based on Haemoglobin Level Variations Induced by Fluid Resuscitation. A Pilot Study.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07733206
Acronym
IFC-sepsis
Enrollment
100
Registered
2026-07-29
Start date
2026-09-15
Completion date
2028-10-15
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Septic shock, capillary leak, endothelial dysfunction, angiopoietin-2, syndecan-1, fluid resuscitation, haemoglobin variation, extracellular water, bio-impedance

Brief summary

This study aims to validate a simple and reproducible index of capillary leak (CLI) in septic shock, based on haemoglobin (Hb) variation induced by standardised fluid resuscitation. To achieve this, the correlation between CLI and biomarkers of endothelial dysfunction-angiopoietin-2 and syndecan-1-will be assessed in both septic and non-septic shock patients. CLI may contribute to the individualisation of fluid management in patients with septic shock.

Detailed description

Septic shock is characterised by systemic inflammation leading to endothelial dysfunction and increased capillary permeability. This results in intravascular hypovolaemia and interstitial oedema, contributing to tissue hypoperfusion and organ failure. Despite the prognostic implications, bedside assessment of capillary leak remains difficult, with no simple or standardised method available. Fluid resuscitation is the first-line therapy for circulatory failure in septic shock, but excessive fluid administration has been associated with increased mortality. Recent trials investigating restrictive fluid strategies have failed to show a survival benefit, likely due to the lack of patient stratification based on the severity of capillary leak. A bedside marker could guide personalised fluid and vasopressor therapy. A standardised fluid bolus (8 ml/kg of ideal body weight, Ringer's lactate) will be administered in both septic and non-septic shock patients. Haemoglobin levels will be measured before and after infusion, and the CLI will be calculated as (Hb pre - Hb post) / Hb pre \* 100. Bioimpedance analysis will be used to estimate extracellular water in selected patients.

Interventions

OTHERTEST GROUP: A standardised fluid bolus of 8 mL/kg of ideal body weight using Ringer's lactate will be administered in septic shock patients.

A standardised fluid bolus of 8 mL/kg of ideal body weight using Ringer's lactate will be administered in septic shock patients. Haemoglobin levels will be measured before and after the infusion, and CLI will be calculated using the following formula: CLI = (Hb pre - Hb post) / Hb pre \* 100 In selected patients, extracellular water volume will be estimated using bioimpedance analysis.

OTHERCONTROL GROUP: A standardised fluid bolus of 8 mL/kg of ideal body weight using Ringer's lactate will be administered in non-septic postoperative patients.

Description: A standardised fluid bolus of 8 mL/kg of ideal body weight using Ringer's lactate will be administered in non-septic postoperative patients. Haemoglobin levels will be measured before and after the infusion, and CLI will be calculated using the following formula: CLI = (Hb pre - Hb post) / Hb pre \* 100

Sponsors

University Hospital Center of Martinique
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Test group (septic shock patients): * Adults admitted to the general ICU within 24 hours with a diagnosis of septic shock * Eligible for blood sampling during daytime hours Control group (non septic shock patients): * Adults admitted to the postoperative ICU within 24 hours after surgery * Need for fluid resuscitation * Eligible for blood sampling during daytime hours * Patients with an arterial catheter in place as part of their care

Exclusion criteria

* \- Clarkson's disease (idiopathic capillary leak syndrome) * Pre-existing extracellular fluid overload (e.g., cirrhosis, decompensated heart failure, nephrotic syndrome, chronic kidney disease on or awaiting dialysis) * Active bleeding or hemolysis * Receiving ECMO * Ongoing renal replacement therapy during the intervention * Blood transfusion within one hour before the intervention * Change in vasopressor or inotrope dose within 30 minutes before the intervention

Design outcomes

Primary

MeasureTime frameDescription
Correlation coefficient between CLI and serum levels of angiopoietin-2 and syndecan-1 at inclusion (Day 0) and on Day 3 in patients with septic shock.04 DAYSCorrelation coefficient between CLI and serum levels of angiopoietin-2 and syndecan-1 at inclusion (Day 0) and on Day 3 in patients with septic shock.

Secondary

MeasureTime frameDescription
Correlation coefficient between CLI at Day 0 and extracellular water accumulation from Day 0 to Day 3, assessed by bioimpedance, in patients with septic shock04 DAYSCorrelation coefficient between CLI at Day 0 and extracellular water accumulation from Day 0 to Day 3, assessed by bioimpedance, in patients with septic shock
Difference in CLI at Day 0 between patients with septic shock and those without.01 DAYDifference in CLI at Day 0 between patients with septic shock and those without.
Odds ratio (95% CI) for the association between 30-day mortality and CLI measured at Day 0 in patients with septic shock.30 DAYSOdds ratio (95% CI) for the association between 30-day mortality and CLI measured at Day 0 in patients with septic shock.

Countries

Martinique

Contacts

CONTACTSARAH-PRESCILLIA JOSEPH, MSC
SARAH-PRESCILLIA.JOSEPG@CHU6MARTINIQUE.FR0596592696
PRINCIPAL_INVESTIGATORPATRICK ROYER, DR

CHU MARTINIQUE

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026